Job Description:
Fred Hutchinson Cancer Center is an independent, nonprofit organization providing adult cancer treatment and groundbreaking research focused on cancer and infectious diseases. Based in Seattle, Fred Hutch is the only National Cancer Institute-designated cancer center in Washington. With a track record of global leadership in bone marrow transplantation, HIV/AIDS prevention, immunotherapy and COVID-19 vaccines, Fred Hutch has earned a reputation as one of the world’s leading cancer, infectious disease and biomedical research centers. Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy and related services, and network affiliations with hospitals in five states. Together, our fully integrated research and clinical care teams seek to discover new cures to the world’s deadliest diseases and make life beyond cancer a reality.  At Fred Hutch we value collaboration, compassion, determination, excellence, innovation, integrity and respect. These values are grounded in and expressed through the principles of diversity, equity and inclusion. Our mission is directly tied to the humanity, dignity and inherent value of each employee, patient, community member and supporter. Our commitment to learning across our differences and similarities make us stronger. We seek employees who bring different and innovative ways of seeing the world and solving problems. Fred Hutch is in pursuit of becoming an anti-racist organization. We are committed to ensuring that all candidates hired share our commitment to diversity, anti-racism and inclusion.  The laboratories of Dr. Gavin Ha and Dr. David MacPherson have a joint postdoctoral research position open in the Computational Biology Program of the Public Health Sciences and Human Biology Divisions. We are seeking a highly motivated individual who is interested in developing and implementing innovative computational and analytical approaches to study the genetics and epigenetics of lung cancer from tumor and liquid biopsies. Candidates who are excited about large/complex ‘omics’ data analysis of cancer genomes, computational methods development, and liquid biopsy research are encouraged to apply. Projects can be completely computational or could also involve wet-lab components, depending on the interests and experience of the applicant.  The position has a competitive salary and great benefits.  The successful candidate will have the opportunity to work on transformative and leading-edge research study in lung cancer research using circulating tumor DNA (ctDNA) from liquid biopsies. This project will involve analysis of ctDNA and methods development to exploit liquid biopsies for detecting and studying small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), discovering new ctDNA biomarkers of treatment response, and to advance precision oncology. For examples of recent studies, see PMID:29109393, PMID: 36399432, PMID: 36463275.   Dr. Ha’s laboratory develops computational approaches to study cancer genomes from tumors and liquid biopsies, such as circulating tumor DNA. He is a recipient of an NIH Director’s New Innovator Award, an NCI Transition Career Development Award, a Prostate Cancer Foundation Young Investigator Award, and a V Foundation Scholar Grant.  Dr. MacPherson is a leading expert in the biology of SCLC whose lab uses in vivo models to identify new therapeutic approaches for this aggressive cancer type. |
